The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity

Vaccine Response Impaired Clinical Trial

Official title:

A Double-blind, Randomized Controlled Trial of the Effect of Vaccine Inoculum on Oral Rotavirus Vaccine (Rotarix, GlaxoSmithKline) Take and Immunogenicity in Dhaka, Bangladesh

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02992197
• Other study ID #: CHRMS 17-0166
• Status: Completed
• Phase: Phase 4
• Start date: June 12, 2017
• Est. completion date: June 7, 2018

Study information

• Verified date: July 2020
• Source: University of Vermont
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rotavirus is the leading cause of diarrhea in children worldwide. Oral rotavirus vaccines work remarkably well in high-income countries, but for unclear reasons they underperform in low-income countries. A double-blind, randomized control trial will be performed to evaluate whether using a higher dose of a currently licensed vaccine (Rotarix, GlaxoSmithKline) can improve immune responses among infants in Dhaka, Bangladesh.

Infants will be randomized 1:1 to receive either a standard or a double dose of Rotarix at 6 and 10 weeks of life. Infants will be assessed for fecal vaccine shedding and serum rotavirus-specific IgA responses to determine vaccine immunogenicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: June 7, 2018
• Est. primary completion date: June 7, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 15 Weeks

Eligibility

Inclusion Criteria:

1. Generally healthy infant (as determined by medical officers)

2. Age 0-7 days at enrolment

3. Mother willing and able to provide signed informed consent

4. Mother willing to allow infant to be vaccinated according to study schedule

5. Mother willing to allow biological specimens, including blood, stool, and saliva, to be collected from infant according to study protocol

6. Mother willing and able to adhere to study schedule

Exclusion Criteria:

1. Obvious congenital malformation

2. Birth weight (if known) or enrolment weight (if birth weight unknown) < 2000 gm

3. Known immunocompromising condition in infant

4. Enrolment in other vaccine research trials

5. Other household member enrolled in this study

Related Conditions & MeSH terms

• Rotavirus Infection
• Rotavirus Infections
• Vaccine Response Impaired
• Vaccine Virus Shedding

Intervention

Biological:
• Rotarix, dose 1
Rotarix, dose 1
• Rotarix, dose 2
Rotarix, dose 2

Drug:
• Placebo (for Rotarix dose 2)
Sterile water to provide volume equivalent as a second dose of Rotarix

Locations

Country	Name	City	State
Bangladesh	International Center for Diarrhoeal Disease Research, Bangladesh (icddr,b)	Dhaka

Sponsors (4)

Lead Sponsor	Collaborator
University of Vermont	Charles H. Hood Foundation, International Centre for Diarrhoeal Disease Research, Bangladesh, Thrasher Research Fund

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number (or Percentage) of Infants in Each Study Arm Who Test Positive for Fecal Rotavirus Vaccine-strain Virus Shedding Post-vaccination	This will be an aggregate measure demonstrating a change from baseline. Infants will have stool collected immediately prior to Rotarix vaccination at weeks 6 and 10 of life, then 4, 7, and 14 days following each dose (i.e. last assessment at week 12 of life). Each specimen will be assessed for vaccine-strain virus (i.e. fecal vaccine shedding) at each time point by polymerase chain reaction. Any child who has a change in fecal vaccine shedding status, from negative at baseline (6 weeks) to positive at any subsequent time point, will be categorized as having met the outcome measure for positive fecal vaccine shedding.	Measured through week 12 of life
Primary	Number (or Percentage) of Infants in Each Study Arm With Rotavirus-specific Plasma Immunoglobulin A (IgA) Seroconversion Post-vaccination	This outcome will measure seroconversion, i.e. the change in plasma rotavirus-specific IgA concentration at week 14 of life compared to week 6 of life (baseline). Blood will be collected from infants prior to the first dose of Rotarix at week 6 of life and again at week 14 of life (4 weeks following the second dose) for measurement of plasma rotavirus-specific IgA by enzyme immunoassay. Infants will be assessed for seroconversion (IgA concentration <=20 U/mL pre-vaccination and >20 post-vaccination). Infants who demonstrate rotavirus-specific IgA seroconversion will be categorized as having met the outcome measure.	Measured at week 14 of life
Primary	Number (or Percentage) of Infants in Each Study Arm With Successful Vaccine Take, Defined as Positive Fecal Vaccine Shedding Post-vaccination OR Rotavirus-specific Plasma IgA Seroconversion Post-vaccination	Vaccine take is an aggregate, dichotomous immunogenicity measure (successful vaccine take vs no vaccine take). Infants positive for either fecal vaccine shedding OR plasma rotavirus-specific IgA seroconversion (as described in Outcomes 1 and 2, respectively) will be categorized as having met the outcome measure of successful vaccine take. Those who met neither outcome will be categorized as no vaccine take.	Measured at week 14 of life